Notably, several investigations involving CYP2D6 polymorphisms have contributed to the refinement of tamoxifen-based therapy in breast cancer patients, enabling a pharmacogenomically guided, individualized treatment strategy [103,104,105]. The gene discussed is CYP2D6; the disease is breast carcinoma.